XOMA Royalty Corporation acquires 50% interest in Twist Bioscience's future milestones and royalties for $15M, expanding its portfolio to 100 assets.
XOMA Royalty Corporation has purchased a 50% economic interest in future milestones and royalties from over 60 partnered early-stage programs with Twist Bioscience for $15 million. This acquisition enhances XOMA's portfolio to over 100 assets, including commercial therapeutics and pre-clinical programs. The deal is aimed at improving risk-adjusted returns for shareholders and strengthens XOMA's position in the biotech royalty sector.
October 22, 2024
4 Articles